Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
4 search results for:

423 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 26-07-2022 | Renal cell carcinoma | News | Article

    KEYNOTE-426 QoL data further support pembrolizumab–axitinib in RCC

    Of the 861 patients included in the study, 429 randomly assigned to receive pembrolizumab plus axitinib and 423 treated with sunitinib had HRQoL data available for the current analysis.

    Author:
    Laura Cowen
    Published in:
    Eur Urol 2022; doi:10.1016/j.eururo.2022.06.009
  2. 18-02-2022 | ASCO GU 2022 | Conference coverage | Article

    Adding niraparib to abiraterone boosts mutated mCRPC outcomes

    The double-blind MAGNITUDE study included 423 patients with alterations in specified HRR genes ( ATM , BRCA1 , BRCA2 , BRIP1 , CDK12 , CHEK2 , FANCA , HDAC2 , or PALB2 ) who had received no more than 4 months of abiraterone plus prednisone for mCRPC.

    Author:
    Shreeya Nanda
    Published in:
    ASCO Genitourinary Cancers Symposium; San Francisco, California, USA: 17–19 February 2022
  3. 10-07-2020 | COVID-19 | News | Article

    New York City data suggest link between immunotherapy, poor COVID-19 outcomes

    The study included 423 patients (56% aged >60 years) who were diagnosed with COVID-19 at MSKCC between 10 March and 7 April 2020 and had a minimum follow-up of 30 days.

    Author:
    Shreeya Nanda
    Published in:
    Nat Med 2020; doi:10.1038/s41591-020-0979-0
  4. 18-10-2016 | Bcr-Abl tyrosine kinase inhibitors | ReviewPaper | Article

    Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

    In a recent analysis 78  of 423 patients who received  de novo  imatinib treatment, 37% had achieved stable MR4.5 by 8 years.

    Author:
    Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, Michele Baccarani
  • 1

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.